Quick Answer
Verrica Pharmaceuticals Inc. reported Long Term Debt of $0.00 for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed a decrease of -100.0% in Long Term Debt from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $34.43 million | Q3 2023: $42.40 million | Q1 2024: $42.85 million | Q2 2024: $42.75 million | Q3 2024: $43.31 million | Q1 2025: $27.81 million | Q2 2025: $24.58 million | Q3 2025: $21.62 million.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $30.98 million | Fiscal year 2023: $42.87 million | Fiscal year 2022: $0.00.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: